Hima Bindu Tam Tam, MD

• Maternal Fetal Medicine Fellow
• North Shore University Hospital
• Manhasset, New York

Dominant renin gene mutations associated with early-onset hyperuricemia medications you can take during pregnancy oxytrol 2.5 mg order line, anemia medications you can give your cat discount oxytrol 5 mg with visa, and chronic kidney failure treatment 4 water order oxytrol with amex. Chromosome 1 localization of a gene for autosomal dominant medullary cystic kidney disease symptoms bladder infection order oxytrol 2.5 mg fast delivery. Tamm-Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation medications diabetes purchase oxytrol 2.5 mg visa. Embryonic lethality in affected hemizygous males is usually reported in the first and second trimesters of pregnancy. The condition was originally described by Papillon-Leage and Psaume in 1954 and better defined in 1962 (Papillon-Leage and Psaume, 1954; Gorlin and Psaume, 1962) and has an incidence estimated between 1/50,000 and 1/150,000 live births (Gorlin et al. Histological examinations of renal tissues demonstrate a predominantly glomerulocystic kidney disease with a small population of tubular cysts (Feather et al. In addition, in contrast to what is observed in autosomal dominant polycystic kidney disease, renal cysts do not alter the contour of the kidneys. Different studies have failed to identify convincing genotype­phenotype correlation. The clinical spectrum the clinical spectrum for this disease includes malformation of the face, oral cavity, and digits with a high degree of phenotypic variability, even within the same family, possibly due to X-inactivation. Craniofacial abnormalities are observed in > 87% of cases and include abnormal hair/alopecia, facial dysmorphisms, and facial milia clefts of lip and palate. Oral signs are present in > 96% of cases and are represented by oral frenula, tongue and teeth abnormalities, and alveolar ridge clefting. Skeletal involvement is reported in about 88% of cases and include brachydactyly, clinodactyly, and syndactyly and rarely polydactyly. Additional signs include hearing impairment and cysts in other organs (pancreas, ovary, liver). Animal models and functional studies Ubiquitous inactivation of the Ofd1 transcript in the mouse resulted in embryonic male lethality and perinatal lethality in females. Affected females displayed craniofacial and limb abnormalities including a severe cleft palate, which is the likely cause of the observed lethality. Although the mutant kidneys had normal external morphology, a highly penetrant polycystic kidney disease of glomerular origin was observed in all cases examined. Conditional mutants with limb- and kidney-specific Ofd1 inactivation in the mouse contributed insights into the functional role of Ofd1 (Zullo et al. Ofd1 disruption in zebrafish supports the role of this transcript in primary cilia function and in the pathogenesis of renal cystic disease (Ferrante et al. Renal cysts are usually observed in the second and third decades of life with few reports of occurrence in the first decade of life and examples of patients in which the renal involvement completely dominates the clinical course of the disease (Coll et al. Limb abnormalities are also a frequent finding and include brachydactyly and clinodactyly (D) and duplication of the allux (E). Arrowheads indicate primary cilia in the wt glomerulus (E), arrows indicate primary cilia in the tubuli of wt (E) and mutant (F); no cilia are observed on the surface of epithelial cells lining the cyst in the mutant (F). Reprinted by permission from Macmillan Publishers Ltd: Nature Genetics, Maria Immacolata Ferrante, Alessandro Zullo, Adriano Barra, Sabrina Bimonte,Nadia Messaddeq et al. Oral-facial-digital syndrome type 1 is another dominant polycystic kidney disease: clinical, radiological and histopathological features of a new kindred. Convergent extension movements and ciliary function are mediated by ofd1, a zebrafish orthologue of the human oral-facial-digital type 1 syndrome gene. Oral-facial-digital type I protein is required for primary cilia formation and left-right axis specification. Mutational spectrum of the oral-facial-digital type I syndrome: a study on a large collection of patients. Renal insufficiency, a frequent complication with age in oral-facial-digital syndrome type I. This matures into a focal adhesion protein complex, which has direct links to the cytoskeleton. During glomerular development, there are two distinct basement membranes produced by endothelial cells and podocytes. As these cell layers come together, the basement membrane coalesces to form a single structure. Functionally, the glomerular filtration barrier allows selective filtration with water and small solutes passing freely through the barrier and macromolecules and cells being maintained within the circulation. This selective permeability is based on molecule size and electrostatic charge with evidence for the latter arising from early studies incorporating the use of charged and neutral dextran molecules (Brenner et al. More recently, investigation has turned to the endothelial sugar coat or glycocalyx to examine its role in maintaining the charge barrier (Friden et al. In addition, basic science research has built understanding about the role of basement membrane-associated proteins in maintaining filtration barrier function. Three different protomers have been identified, with the compositions 112, 345, and 556 (in this terminology, 112 indicates a protomer made up of two 1 and one 2 chains, and so on). However 556 protomers appear to associate with 112 protomers in a common network (Borza et al. This network is thought to be more able to withstand hydrostatic pressures and more resistant to proteolysis, and therefore maintains structural support within the filtration barrier. Further crosslinking of the network is thought to enhance tensile properties and thus provide a strong structural support for the overlying cells. A similar phenomenon is occasionally observed in patients with Alport syndrome following renal transplantation (Chapter 75). Individuals are heterozygote for these mutations and in the absence of proteinuria or hypertension, this condition has been termed benign familial haematuria. It is unclear whether modifying genes are contributing to progression of the renal phenotype in individuals who develop severe phenotypes. Through complex interactions, these molecules can interact further to form higher-order supramolecular organization and three-dimensional networks. The networks are further enforced by supramolecular twisting and lateral associations of their collagenous domains. These mutations result in multisystem pathology in which renal disease is usually a minor manifestation. Inheritance is generally autosomal dominant and haematuria may be the result of defective tubular and peritubular capillary basement membranes resulting in leakage of red blood cells. Five chains, four chains, and three gamma chains combine to create 15 distinct laminin isoforms which have tissue-specific expression. The nomenclature for laminins is taken from the chain number therefore laminin 521 is termed laminin-521 (Aumailley et al. Both podocytes and endothelial cells have been shown to contribute to the synthesis of this laminin isoform (Steenhard et al. Furthermore, reduced expression of laminin 5 was associated with proteinuria, haematuria, and polycystic kidneys (Shannon et al. In additional studies, absence of laminin 2 led to early-onset nephrotic syndrome (Noakes et al. In this mouse model, overexpression of laminin 1 improved the phenotype, suggesting that excess 1 could compensate for the absence of the 2 laminin chain. Human mutations in laminin 2 have also been described and result in Pierson syndrome (Zenker et al. The syndrome is characterized by neonatal nephrotic syndrome, eye defects including microcoria, and abnormalities of neuromuscular junctions. Fibronectin is expressed in the normal glomerulus where it is predominantly localized in the mesangium. Individuals exhibit proteinuria, haematuria, and progression to renal failure between the second and sixth decades. The double-nidogen knockout mouse has perinatal lethality and whilst basement membranes develop, the absence of both nidogens is critical for the late stages of lung and cardiac development (Bader et al. A small proportion of these mice had unilateral or bilateral renal aplasia suggesting overall that the function of nidogens in the kidney can be compensated by other mechanisms. This suggests that the role of nidogens may be more important in protection from glomerular injury. These proteins have a strong anionic charge (McCarthy and Wassenhove-McCarthy, 2012) and this property was considered to be an important contributor to barrier integrity. The agrin gene was deleted specifically in podocytes and the mice did not develop proteinuria. The same was true with the perlecan podocyte-specific knockout and also the double agrin­perlecan knockout (Goldberg et al. This was also examined using a different approach by deleting the enzyme Ext1 from podocytes. To date, neither perlecan nor agrin mutations have been described in human disease. Nail-patella syndrome this multisystem disorder (see Chapter 326) includes dystrophic nails, absence or hypoplasia of the patella, and nephropathy. The latter can range from mild proteinuria to nephrotic syndrome and 30% of patients with nephropathy will progress to renal failure. C-terminal cleavage of the protein releases endostatin, which has anti-angiogenic properties. The activated receptor then initiates a cascade of signalling events which direct cell behaviour. Adhesion receptors have ligand and tissue specificity and within the glomerulus the predominant adhesion receptors are integrins and dystroglycan. Mouse genetic studies have highlighted the importance of the laminin receptor integrin 31 with the 3 knockout mouse, which develops lung and kidney defects (Kreidberg et al. Podocyte specific deletion of the 3 subunit also resulted in Fibronectin Fibronectin is a high-molecular-weight glycoprotein, which has key roles in cell adhesion, differentiation, and migration. More recently, human integrin 3 homozygous mutations have been associated with basement membrane abnormalities in kidney, lung, and skin (Has et al. In the reported case series, clinical presentation combined congenital nephrotic syndrome, epidermolysis bulosa, and interstitial lung disease. In further mouse studies, homozygous deletion of integrin 1 led to embryonic lethality (Fassler and Meyer, 1995), which may explain the absence of known human mutations in this integrin subunit. However, the podocyte-specific deletion of 1 demonstrated the importance of this integrin in glomerular function (Pozzi et al. The mice developed early renal failure and podocyte effacement was seen followed by podocyte apoptosis and degeneration of the glomerular capillaries and mesangium, thought to be secondary to concomitant loss of podocyte-derived growth factors. The adhesion receptor dystroglycan binds agrin, perlecan, and laminin and the role of this receptor has also been investigated in mouse models. The podocyte-specific deletion of this protein did not result in a renal phenotype (Jarad et al. However, interruption of receptor glycosylation was associated with altered podocyte architecture suggesting that this receptor has a minor role in maintaining barrier integrity. Compound genetic ablation of nidogen 1 and 2 causes basement membrane defects and perinatal lethality in mice. Glomerular permselectivity: barrier function based on discrimination of molecular size and charge. Global analysis reveals the complexity of the human glomerular extracellular matrix. The glomerular basement membrane as a model system to study the bioactivity of heparan sulfate glycosaminoglycans. The renal glomerulus of mice lacking s-laminin/laminin beta 2: nephrosis despite molecular compensation by laminin beta 1. Beta1 integrin expression by podocytes is required to maintain glomerular structural integrity. A hypomorphic mutation in the mouse laminin alpha5 gene causes polycystic kidney disease. Human laminin beta2 deficiency causes congenital nephrosis with mesangial sclerosis and distinct eye abnormalities. Loss of heparan sulfate glycosaminoglycan assembly in podocytes does not lead to proteinuria. Glomerular filtration is normal in the absence of both agrin and perlecan-heparan sulfate from the glomerular basement membrane. Disruption of glomerular basement membrane charge through podocyte-specific mutation of agrin does not alter glomerular permselectivity. Dystroglycan does not contribute significantly to kidney development or function, in health or after injury. Those affected by the autosomal recessive variant are phenotypically very similar. Its molecular structure and the biochemical composition of the glomerular basement membrane are described in Chapter 320. Light microscopy examination of renal biopsies does not show any specific changes. Angiotensin-converting enzyme inhibitors probably slow the progression of Alport syndrome substantially, and should be prescribed at full or maximum tolerated dose to all males affected by X-linked disease, and to all individuals with autosomal recessive disease, and to all carriers who have proteinuria (see Chapter 324). Hearing impairment commonly develops during high school years and can be a significant burden but rarely leads to total loss of hearing. These features contrast to some of the other causes of hearing impairment with kidney disease (see Chapter 170). Patients with Alport syndrome generally do well on dialysis or after renal transplantation. Cecil Alport (Alport, 1927) had been studied since the beginning of the twentieth century. This statement has subsequently been largely confirmed: X-linked dominant inheritance is the most frequent mode of inheritance in this disorder (80­85% of the families). This proportion is probably underestimated since Alport syndrome is underdiagnosed in small kindreds or in sporadic cases, particularly if the characteristic hearing defect is not present at the time the index patient presents. The rate of progression to renal failure is heterogeneous and depends on sex and genetic factors (Jais et al.

In a follow-up report treatment for piles cheap oxytrol american express, Fabry also documented the presence of albuminuria (Fabry medicine descriptions discount oxytrol 5 mg without prescription, 1930) treatment broken toe buy 2.5 mg oxytrol with visa. Several other descriptions followed expanding the clinical associations and in 1947 Pompen and colleagues reported the first post-mortem cases of two brothers who died of renal failure (Pompen et al treatment 8th march generic 5 mg oxytrol fast delivery. The most important finding was the presence of vacuoles in blood vessels throughout the kidney leading them to postulate that this was a generalized storage disease everlast my medicine order oxytrol 2.5 mg line. Subsequently, this was confirmed by Scriba who established the lipid nature of the storage material (Scriba, 1950). The storage material was characterized as neutral glycosphingolipids, including globotriaosylceramide (Gb3) (Sweeney and Klionsky, 1963) and then Brady and colleagues demonstrated that the accumulation of lipid resulted from a defect in the enzyme ceramide trihexosidase (Brady et al. The hereditary nature of the condition had been known for some time but it was not until 1965 that Opitz and colleagues documented the X-linked nature of the condition (Opitz et al. In 1986, the gene responsible for the disease was characterized and sequenced (Bishop et al. While Gb3 accumulates in Fabry disease some is de-acetylated to form lyso-Gb3 by a mechanism that is, as yet, not understood (Aerts et al. Glycosphingolipids are widely distributed in the body as constituents of normal plasma membranes (Thompson and Tillack, 1985) and some intracellular membranes such as those of the Golgi and lysosome (Dawson, 1978). In the plasma they are associated with lipoproteins with high concentrations in the low-density lipoprotein fraction (Kundu et al. Pathophysiology the exact mechanisms behind the organ damage in Fabry disease is still not clear. As there are no clinical symptoms in infancy, and rarely in early childhood, the damage must be related to the slow accumulation of Gb3 and allied compounds, starting in utero (Tsutsumi et al. Using unbiased stereological quantitative methods to analyse electron microscopic changes in 14 young Fabry disease patients and controls, the podocyte Gb3 inclusion volume density increased progressively with age. Foot process width was increased and also increased with age as did a reduction of endothelial fenestrations (Najafian et al. While this may be the first stage of renal damage, the ultimate progression to end-stage renal failure is certainly multifactorial. Valbuena and colleagues hypothesized that the initial trigger may be the rupture of the lysosome after a certain amount of substrate accumulation with subsequent cell death (Valbuena et al. Oxidative stress may also play a role as when Gb3 was added to cultured vascular endothelial cells there was a dose-dependent increase in the production of reactive oxygen species and upregulation of the expression of cell adhesion molecules (Shen et al. A vasculopathy also seems to occur in many patients where there is little, if any, endothelial deposition but smooth muscle cell hypertrophy occurs and is often one of the first features to appear followed by changes in the neo-intima and subsequent fibrosis. The local Biochemistry the -galactosidase A enzyme is one of many acid hydrolases found in the lysosome. The result of deficiency or absence of the enzyme leads to the accumulation of the substrate, predominantly Gb3. The enzyme is a homodimeric glycoprotein with each monomer composed of a (beta/alpha) 8 domain with the active site and an antiparallel beta domain. N-linked carbohydrate appears at six sites in the glycoprotein dimer, revealing the basis for lysosomal transport via the mannose-6-phosphate receptor (Garman and Garboczi, 2004). However, it should be noted that there are other systems that can transport enzyme into a cell (see Chapter 338). Interestingly these changes were prevented by paricalcitol, raising the possibility that vitamin D receptor activation may be a potential adjuvant therapy. Although the above processes are almost certainly important in pathogenesis of renal damage in Fabry disease, the question still arises as to how all this follows from the accumulation of Gb3 in the lysosomes of various cell types within the kidney. One clue may lie in the fact that there is dysregulation of autophagy in the podocytes in Fabry disease (Liebau et al. A metabolomic study reveals novel plasma lyso-Gb3 analogs as Fabry disease biomarkers. The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. Possible role of transforming growth factor-1 and vascular endothelial growth factor in Fabry disease nephropathy. Angiokeratoma corporis diffusum (universal) Fabry, as a sign of internal disease: two autopsy reports. Vasculopathy in patients with Fabry disease: current controversies and research directions. An association study of inflammatory cytokine gene polymorphisms in Fabry disease. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Zur pathogenesis des angiokeratoma corporis diffusum Fabry mit cardio-vasorenalem symptomen complex. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Organisation of glycosphingolipids in bilayers and plasma membranes of mammalian cells. Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy. The condition is pan ethnic with an estimated incidence of between 1/40,000 and 1/120,000 live births (Mehta et al. However, a much higher incidence has been found, consisting mostly of late-onset phenotypes (see below), as a result of newborn screening initiatives. The majority of classical patients have either nonsense or missense mutation resulting in non-functional, misfolded, or absent enzyme. The symptoms tend to come on at a later age and are generally milder with many women asymptomatic throughout their lives. This is due to the inactivation of one of the alleles of the alpha-galactosidase gene (Romeo and Migeon, 1970). Generally, patients can be divided into three categories-the classical male patient, the later-onset cases, and the female heterozygotes. Life expectancy Irrespective of how the disease manifests, it results in a decreased life expectancy with males dying at a mean of 58. The commonest causes of death from the same publication indicate that cardiovascular and renal events account for the majority of Fabry-related deaths. When considering all the presentations of Fabry disease, 62% of patients present with neuropathic pain, 31% with skin lesions, 19% with gastrointestinal problems, and 17% with renal disease. However, in males the mean age at diagnosis is not until 23 years and in females not until 32 years indicating a significant diagnostic gap (Eng et al. While this diagnostic gap may have reduced slightly since 2007, it is still important to emphasize, as will be demonstrated below, because early diagnosis gives the best outcomes. The median age of symptom onset is 6 years for boys and 9 years for girls (Hopkin et al. The most common symptoms are neuropathic pain found in 59% of boys and 41% of girls together with gastrointestinal symptoms present in 18% of children (Hopkin et al. The pain often decreases in severity later in life and, unless explicitly asked about, can be missed when adult patients are first seen and questioned in clinic (Naleschinski et al. The abdominal pain is caused by deposition of Gb3 in the abdominal autonomic ganglia and decreased flow in the mesenteric artery, again due to substrate deposition in the endothelium and muscular layer causing narrowing of Heterogeneity While Fabry disease affects multiple organs there is great heterogeneity both within families sharing the same gene mutation and between families with different mutations but the same level of enzyme deficiency. The reasons behind this phenomenon are not known, but it has major implications for genetic counselling and for predicting final phenotype when seeing patients in the clinic. Although there is some correlation between disease severity and enzyme level, with the most severe cases having very low or absent plasma enzyme, there is no correlation between the enzyme level or mutation and the way that the disease is manifest. Renal biopsy findings in children and adolescents with Fabry disease and minimal proteinuria. The pain is very similar to that found in irritable bowel syndrome which enters into the differential diagnosis (Hoffmann et al. Also occurring early in the course of disease, due to a mixture of autonomic neuropathy and deposition of Gb3 in the sweat glands, is anhidrosis, or in some cases partial loss of sweating, that can be quite debilitating (Kang et al. It is estimated that around 53% of males and 28% of females complain of some degree of sweating problems (Orlev et al. In the cohort of patients managed by the Melbourne Fabry Disease Treatment Centre, 94. Vision is rarely impaired, although a small number of patients do develop Fabry cataracts-23. Fabry patients also display increased tortuosity of the retinal vessels that has been reported to be associated with an increased severity of the disease (Sodi et al. Histologically, they are caused by dilatation of vessels-capillaries and venules-associated with deposition of substrate in the endothelium of the dermal vasculature (Brethnach et al. Clinically, these characteristic lesions are red or purple and can be flat or slightly raised. They are characteristically found between the umbilicus and the mid thigh-the so-called bathing trunk area-and are relatively symmetrical in distribution. However, they can be found anywhere on the body-even on the lips-and may be quite solitary. When concentrated around the umbilicus and on and around the genitalia they can be very unsightly and add to the psychological stress of a patient. In severe cases, where the lesions are very prominent and in large coalescent patches, they can bleed. Some form of skin lesion is found in around 66% of male and 36% of female patients (Orlev et al. Although less common, lymphoedema can be very debilitating for patients and occurs in 16% of male and 6% of female patients (Orlev et al. There have even been reports of early evidence of early microvascular disease affecting the central nervous system (Cabrara-Salazar et al. Cardiac involvement is one of the most common features of Fabry disease, both in hemizygous males and heterozygous females, and is a major source of morbidity and mortality. Deposition of Gb3 occurs in a wide variety of cell types including cardiac myocytes, vascular endothelial cells, cardiac conducting tissue, and fibroblasts of the cardiac valves. The resulting clinical effects are progressive cardiac hypertrophy with reasonably well preserved cardiac function till late in the disease process; a wide range of arrhythmias, mitral valve prolapse, and angina, as well as a dilated aortic root (Linhart, 2006). While these can be seen as a result of long-term therapy with chloroquine and amiodarone, if patients are not taking these drugs, the presence of theses corneal changes can be considered diagnostic of Fabry disease. The typical changes start in the posterior lateral section of the left ventricle and during progression there is also evidence of fibrosis in that area. However, in female heterozygotes it is not uncommon to get fibrosis without evidence of hypertrophy (Neimann et al. However, diastolic dysfunction is common and occurs quite early in the course of the disease (Linhart, 2006). In a retrospective case note study of 447 patients, 42% of male and 27% of female patients had an arrhythmia (Schiffmann et al. In another study, the patients were divided into the various types of rhythm disturbance and showed paroxysmal atrial fibrillation in 13. Syncope may also occur and, although arrhythmia may be partly to blame, cardiac autonomic dysfunction could also be a contributing factor (Lobo et al. As with many of the other lysosomal storage diseases, mitral valve involvement is quite common although surgical intervention is rarely required (Sakuraba et al. While there is little aortic valve involvement, dilatation of the aortic root has been reported, but the clinical significance is unclear (Bass et al. Myocardial infarction is also rare but angina is reasonably common, occurring in around 60% of patients, and is due to reduced flow in the coronary microcirculation as a result of deposition of Gb3 (Elliott et al. As well as angina, significant numbers of patients also have cough and wheeze due to pulmonary involvement with 36% showing an obstructive ventilation defect (Brown et al. While transient ischaemic attacks also occur to excess in Fabry patients, the true incidence is unclear due to problems in definitions and data collection. Gubler and colleagues had previously described Fabry disease in children (Desbois et al. More recently, using registry data, overt proteinuria has been described in boys and girls in their early teenage years (Reis et al. Once proteinuria has developed renal function declines at a variable rate between 2. It is also of note that patients with significant renal impairment have a far higher incidence of other Fabry complications, and present at a far later stage of the disease, than those without renal involvement (Ortiz et al. Even though proteinuria is the most sensitive marker of early renal involvement in Fabry disease, microscopic haematuria has also been described (Sheu et al. However, there have also been reports of immunoglobulin A nephropathy and thin basement membrane disease occurring concomitantly in patients with Fabry nephropathy (Whybra et al. Lastly, classical male patient are thought to have slight facial dysmorphism with thick-set features, especially around the orbits and eyebrows (Cox-Brinkman et al. Cochlear features Tinnitus affects many patients in childhood and early adolescence (Reis et al. A review of 109 patients-85 males age range 6­58 years and 24 females aged 22­72 years-showed that 56% had a hearing deficit. The hearing loss in males was more profound in those who had the most evidence of cerebral small vessel disease in the form of white matter lesions. Nevertheless, the predominant defect was found to be cochlear in origin (Reis et al. Fabry patients often complain of headache and can have symptoms similar to migraine with an aura (Albano et al. Heterozygous females the traditional view had been that, as an X-linked disease, female heterozygotes would be carriers with a very low incidence of symptoms. However, quite early on it was recognized that females can be affected (Wise et al. In the first report of a large cohort of female patients MacDermot and colleagues found that, out of 60 obligate carrier females, 70% had neuropathic pain and in 27. They also reported that survival was 70 years of age some 15 years shorter than the normal population (MacDermot et al.

Serine proteinase inhibitor-9 medications ending in pril cheap oxytrol 2.5 mg amex, an endogenous blocker of granzyme B/perforin lytic pathway treatment 3 cm ovarian cyst generic 5 mg oxytrol amex, is hyperexpressed during acute rejection of renal allografts medications while pregnant oxytrol 5 mg order with amex. Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantation medicine guide oxytrol 2.5 mg purchase line. Histological findings in early routine biopsies of stable renal allograft recipients treatment breast cancer 5 mg oxytrol sale. Beneficial effects of treatment of early subclinical rejection: a randomized study. Detection of subclinical tubular injury after renal transplantation: comparison of urine protein analysis with allograft histopathology. Proteomic-based detection of urine proteins associated with acute renal allograft rejection. Proteomic-based identification of cleaved urinary beta2-microglobulin as a potential marker for acute tubular injury in renal allografts. B cells in cluster or in a scattered pattern do not correlate with clinical outcome of renal allograft rejection. Serial peripheral blood perforin and granzyme B gene expression measurements for prediction of acute rejection in kidney graft recipients. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Detectable circulating antiendothelial cell antibodies in renal allograft recipients with C4d-positive acute rejection: a report of three cases. Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Urinary cytotoxic molecular markers for a noninvasive diagnosis in acute renal transplant rejection. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. In general, the intensity of immunosuppression is at its highest for a year after solid organ transplant (Jong and Freedman, 2012). Guidelines on diagnosis, treatment, and prevention of many infections after solid organ transplant have been provided by the Infectious Diseases Community of Practice of the American Society of Transplantation (2013). In the first month after organ transplant, infections tend to be related to the surgical procedure and hospital environment, and include wound infection, consequences of anastomotic leaks and ischaemia, aspiration pneumonia, catheter infection, and Clostridium difficile colitis. Donor-derived infections and recipient-derived infections, due to prior colonization with agents such as Aspergillus or Pseudomonas, may present in this phase. Their risk can be mitigated or delayed by prophylaxis, and increased by intensified immunosuppression, leucopenia, or immunomodulatory viral infections. The stable and relatively healthy organ transplant recipient who is > 6 months out from transplant tends to develop community-acquired or ordinary infections, including urinary tract infections, upper respiratory infections and pneumonia, gastroenteritis, and varicella zoster. Pre-transplant evaluation can mitigate the risk of some infections, especially latent ones. Potential transplant recipients and donors are screened for latent tuberculosis, by history, chest X-ray, skin testing, or use of an interferon gamma release assay-based blood test such as the T. Recipients from or in endemic regions should be screened for latent infections such as T. Those subjects seronegative for measles, mumps, rubella, hepatitis A and B, and varicella should be vaccinated pre transplant. Some vaccines are live so cannot be given after transplant when the recipient is immunosuppressed (Jong and Freedman, 2012). For example, transplant recipients infected with West Nile virus are much more likely to have clinical illness and succumb. Clinicians need to consider a broad differential diagnosis in transplant recipients. The diagnosis of emerging, novel, and atypical pathogens is especially challenging in this vulnerable population, as has been seen with cases of lymphocytic choriomeningitis virus, tuberculosis, Chagas disease, and strongyloidiasis. Such infection occurs in up to 1% of deceased donor organ transplants (Ison and Nalesnik, 2011). Such unanticipated donor-derived infections range from viruses such as rabies, lymphocytic choriomeningitis and West Nile virus, to bacteria including tuberculosis, fungi including cryptococcosis and histoplasmosis, and parasites such as Trypanosoma cruzi (causing Chagas disease) and Strongyloides stercoralis (Ison and Nalesnik, 2011). Enhanced appreciation of donor-derived infections has resulted in better screening and diagnosis. Infections tend to occur in fairly predictable phases after solid organ transplant. While many of the classic opportunistic infections occur in the first six months, the period of most intense immunosuppression, the risk of such infection is indefinite and still exists for a period after discontinuation of immunosuppressive drugs. The risk of infection is decreased by the use of prophylaxis, and increased by the use of more potent immunosuppression (both in the induction and maintenance phases, and after treatment of rejection), allograft rejection itself, concomitant infections, leucopenia, and technical complications of surgery. Viruses: prophylaxis, diagnosis, and management Viruses are the most common cause of infection after transplantation. Viruses of the human herpes virus family are the most common viral pathogens after transplantation. Disseminated infection from any of the human herpes viruses can be life-threatening. Recipients who acquire de novo infection from their donors, who do not have prior immunity to these viruses, are at highest risk for severe infection. Hepatitis viruses (primarily B and C) are common reasons for liver transplantation and commonly complicate transplantation, predominantly as reactivation of latent infections. The primarily zoonotic hepatitis E has been reported as an emerging pathogen in transplant recipients. Numerous other viruses have been shown to cause disease in transplant recipients, including parvovirus B19, West Nile virus, and lymphocytic choriomeningitis. These outcomes fall somewhere in the national database between kidney transplant recipients who are > 65 years old and those reported for all kidney transplant recipients. Multivariate analysis showed that the risk of graft loss was increased among patients treated for rejection and those receiving antithymocyte globulin induction therapy, while living-donor transplants were protective. A higher-than-expected rejection rate was observed, with 1-year and 3-year estimates of 31% and 41%, respectively. Disadvantages include lower rates of graft and patient survival, higher rates of opportunistic infections, and more complex logistics (organizing and managing the results of weekly testing for several months after transplant). Institutions should develop local protocols, based on clinical outcomes, use of cytolytic induction therapies, the overall state of immunosuppression, costs, and ability to do periodic testing. Compelling data comes from a randomized clinical trial of valganciclovir prophylaxis (N = 74) versus pre-emptive therapy with intravenous ganciclovir (N = 74). Prophylaxis significantly improved long-term graft survival 4 years after transplant (92. Costs of serial testing (including personnel and laboratory costs) may be similar to the costs of medications. It is, however, better to focus on long-term outcomes and overall cost and benefit to the patient and to the programme. Universal prophylaxis incurred $1464 more direct costs compared with pre-emptive therapy, while saving $7309 in indirect costs, and resulted in a net gain of 0. Thus, universal prophylaxis resulted in a cost saving of $27,967 for one quality-adjusted life year gained when compared with pre-emptive therapy. Prophylaxis Viral infections can be prevented by the use of antiviral drugs, prudent use of immunosuppression, administration of immunoglobulins, careful monitoring, and vaccination. Prophylaxis against hepatitis C is not usually given, because toxicity outweighs the benefit. The duration of prevention varies among transplant units, but many programmes prescribe antivirals for 3­6 months after the organ transplant. Universal prophylaxis involves giving antiviral medication at prophylactic doses for a defined period of time to a cohort. Pre-emptive therapy is defined as use of treatment dose antivirals only once a certain test threshold is achieved. Although large, randomized trials have not been conducted, numerous studies suggest that universal prophylaxis results in better outcomes than those achieved with pre-emptive therapy, especially in the higher risk D+/R- population (Kotton et al. Ganciclovir only works in the very small percentage of virus that is in the lytic phase. The 10-year analysis revealed the 200-day prophylaxis as cost saving with a 2380 quality-adjusted life year gain (per 10,000 patients) and simultaneously lower cost. Miscellaneous Mosquito-borne infections such as West Nile virus, dengue fever, eastern equine encephalitis, chikungunya, and others can cause significant disease in transplant recipients. Avoidance of insect bites by wearing protective clothing, using insect repellent, and screens or sleeping nets will decrease the risk of transmission. Vaccination against influenza, hepatitis A and B, human papillomavirus, varicella zoster, and other viral pathogens can provide protection. This is best given prior to transplant, as the immunologic response is likely to be augmented. Certain viral vaccines have live attenuated virus and cannot be used after transplant, such as varicella zoster, measles, mumps, rubella, and yellow fever. In general, transplant centres are much more inclined to administer vaccines to transplant patients than previously, and influenza vaccine is recommended by numerous experts (Kumar et al. Surveys in 1999 and 2009 of United Network for Organ Sharing-certified kidney and kidney-pancreas transplant centres in the United States regarding their influenza vaccination practices established that the 2009 respondents, compared with 1999, were more likely to recommend vaccination for kidney (94. While there has been some concern that vaccines could disrupt tolerance or increase the risk of rejection, this has not so far been borne out in trials. When possible, it is recommended that transplant recipients avoid the adjuvants in some vaccines, and be given vaccines without adjuvants, which are immunostimulatory molecules (Kumar et al. The primary method of prevention is screening, and the primary method of treatment is reduction in immunosuppression. Antiviral therapy, including cidofovir and leflunomide, has an uncertain effect with significant toxicity. Diagnosis Viral infection diagnosis has been improved hugely by the availability of molecular techniques. Within a matter of hours, various amplification methods can precisely identify active replicating viral infections. In general, serology is much less helpful in the immunosuppressed population, as they are much less likely to seroconvert in response to the acute illness, and molecular diagnostics have a much higher yield. Hepatitis B Hepatitis B is a common cause of cirrhosis and the need for liver transplant. Post-transplant management may include antiviral agents such as lamivudine, entecavir, adefovir, and others, as well as the use of hyperimmune hepatitis B globulin. Other organ transplant recipients may have latent hepatitis B, which can reactivate after induction of immunosuppression, especially in those who have hepatitis B surface antigen, and much less commonly in those who have a negative surface antigen but a positive core antibody. If they are non-immune, all patients undergoing dialysis who are candidates for organ transplantation should undergo vaccination in the pre-transplant period. Some patients may need a higher dose of vaccine, and accelerated vaccine series especially if they will be undergoing organ transplantation soon. Chemoprophylaxis is encouraged for those with latent tuberculosis, or who may have exposure via their donor (Morris et al. Vaccination against Streptococcus pneumoniae, Clostridium tetani (tetanus), Corynebacterium diphtheriae, Bordetella pertussis (whooping cough), and other bacterial pathogens will provide some additional protection. Reducing the intensity of immunosuppression (even transiently) may allow for more rapid clearance of a viral infection. Although not well evidence-based, repleting recipients who have hypogammaglobulinaemia with intravenous immunoglobulin may help clear infection. To optimize the diagnostic yield of cultures, clinicians should notify the laboratory when unusual organisms are suspected, such as Listeria, Rhodococcus, mycobacteria, and Nocardia. Expanding the standard panel of antibiotic sensitivity at the time of initial diagnosis may help with subsequent therapy, especially given the increased risk of drug interactions and side effects, partly due to concomitant use of multiple medications. Serologic techniques tend to yield diagnoses less frequently in this population due to more muted immunologic responses. Histopathology, especially with special stains for microorganisms, can sometimes be helpful in achieving a diagnosis; examples include the Fite stain for mycobacteria, the May­Grunwald Giemsa stain, and the Warthin­Starry or Steiner stain for spirochaetes. Management Treatment in febrile or ill transplant recipients is with empiric antibacterial therapy, which should be chosen based on local epidemiology. This approach is justified by the significant incidence of bacteraemia in the post-transplant period and by the concomitant high mortality rate when treatment is delayed. Transplant patients are at higher risk for resistant pathogens, and the empiric antibiotic choice should reflect this. Once a culture diagnosis has been made and antibiotic sensitivities are available, the antibiotic regimen may be modified. Optimal duration of therapy has usually not been well studied in this population, but is often longer than in normal hosts. Certain antibiotic classes should be avoided when possible due to toxicities and side effects. Examples include aminoglycosides (which can increase the risk of renal toxicity) and rifamycins (rifampin/rifampicin or rifabutin, which have profound interactions with tacrolimus and ciclosporin). Because of the increased rates of resistance resulting in decreased susceptibility to oral antibiotics, intravenous therapy is often needed in this population. In general, arm veins should be avoided to preserve them for future haemodialysis access in those at higher risk for chronic kidney disease. Drainage of collections by radiographically or surgically placed drains helps clear infection and prevent recurrence. Appropriately drained infections do not necessarily need long-term antibiotics while the drain stays in place. Preventative measures include eliminating any nidus of infection (such as intravascular catheters, indwelling urinary catheters, stents, skin defects that encourage abscess formation,) and dealing with anatomical problems.

Subsequent chapters will draw on this information when considering the effects of specific drugs on our patients treatment plan for ptsd purchase oxytrol amex. The generic name (also known as the official or nonproprietary name) tends to be somewhat shorter and is often derived from the chemical name medicine cards buy oxytrol 2.5 mg without a prescription. A trade name (also known as the brand name) is assigned to the compound by the pharmaceutical company and may or may not bear any reference to the chemical and generic terminology medicine go down order oxytrol without a prescription. An additional problem with trade names is that several manufacturers may be marketing the same compound under different names medications ibs purchase 2.5 mg oxytrol mastercard, adding to the confusion symptoms of the flu order oxytrol with american express. Different drug companies may market the same drug if there is no existing patent for that compound or if the patent has expired. Drug nomenclature is also a source of confusion and potential errors when different drugs have names that look or sound alike. Despite their similar brand names, these three products represent three distinct pharmacological classes that are used in very different clinical situations. Hence, practitioners need to be especially careful when documenting the use of specific medications and make sure that the correct drug name is used to identify each product. In addition, patients are often concerned that a generic drug may represent a different and less effective product than its trade (brand) name counterpart. The generic drug is typically less expensive than its brand-name counterparts, and substitution of a generic drug can help reduce health-care costs. Likewise, establishing bioequivalence of a generic form does not guarantee that a given patient will not experience different effects from the generic form compared with the brand-name product. This seems especially true for drugs that tend to produce a wider range of therapeutic and adverse effects when tested in a specific patient or within a group of patients. Nonetheless, rehabilitation specialists should be able to explain the rationale for why a generic form of the drug might be prescribed but should also refer their patient to the physician or pharmacist if the patient has additional concerns about the effects of the generic drug. The two primary concerns of these agencies are (1) whether the drug is effective in treating a certain condition and (2) whether the drug is reasonably safe for human use. Drug Approval Process the development of a new drug involves extensive preclinical (animal) and clinical (human) studies. Animal (Preclinical) Studies Drugs are typically tested in animals initially, often using several different species. The animal trials provide preliminary information on the pharmacokinetic and pharmacodynamic properties of the compound and information on dosage and toxicity. The drug is tested in a relatively small sample (50 to 500 people) with a specific disease or pathological condition. The clinical evaluation is expanded to include more patients (several hundred to several thousand) and more evaluators. At this point, the drug can be marketed and prescribed for use in the general population. Postmarketing surveillance refers to all of the methods used to continue monitoring drug safety and effectiveness after approval for public use. In addition to monitoring adverse effects, postmarketing surveillance can use more formal research methods to obtain information about how a specific drug is used in clinical practice and how that drug compares to similar drugs on the market. The exact amount of time that is saved by expedited review and approval depends on which provisions are granted for each drug and how well the drug meets the terms of the acceleration process. Likewise, these expedited drugs may be made available for patient use even before formal clinical testing is completed. Out of thousands of newly synthesized compounds that begin preclinical (animal) trials, only one will ever be released as a prescription drug for use in humans. Research into the development of these drugs may be difficult, and the cost of developing these drugs may be prohibitive given the relatively small amount of people who will eventually use the drug. For example, antiseizure drugs such as gabapentin (Neurontin) and antidepressants such as fluoxetine (Prozac) are often prescribed off-label for treating chronic pain. Practitioners have the ability to prescribe the drug for other conditions based on their judgment and evidence from additional research. But problems arise when insurance companies fail to recognize the use of a drug beyond the approved indications and might therefore refuse to reimburse the cost of the drug. Practitioners may also be subjected to more rigorous legal prosecution if a patient experiences serious adverse effects during off-label drug use. These medications have been judged to be safe for use by the consumer without direct medical supervision, and the chances of toxic effects are usually small when the medications are taken in the recommended amounts. Some common examples include ibuprofen (Advil, Motrin; see Chapter 15), loratadine (Claritin; see Chapter 26), and cimetidine (Tagamet; see Chapter 27). The fact that more and more prescription drugs are now available in a nonprescription form offers some obvious benefits. Examples include certain antianxiety drugs (meprobamate), certain barbiturates (barbital, phenobarbital), and a variety of other depressants and stimulants. Drugs in this category consist primarily of low doses of opioids that are used in cough medications and antidiarrheal preparations. Several other criteria relate to the different controlled substance schedules, such as restrictions on prescription renewal and penalties for illegal possession of drugs in different schedules. For a deeper discussion of controlled substances, the references at the end of this chapter include additional sources. The Comprehensive Drug Abuse Prevention and Control Act (or Controlled Substances Act) placed drugs into specific categories, or "schedules," according to their potential for abuse. These drugs are regarded as having the highest potential for abuse and are not typically used as an acceptable medical treatment in the United States. Legal use of agents in this category is typically restricted to research studies by properly approved and registered researchers. Drugs in this category are approved for specific therapeutic purposes but still have a high potential for abuse and possible addiction. Examples include opioids, such as morphine and fentanyl, and drugs containing amphetamine derivatives. The drug in some way changes the function of the cell either to help restore normal physiological function or to prevent a disease process from occurring. In general, the dose of a drug must be large enough to allow an adequate concentration to reach the target site and produce a beneficial response. However, the administered dosage must not be so excessive that it produces toxicological effects. Some key aspects of the relationship between dose and response are discussed here. In particular, a dose-response curve provides information about the dosage range over which the drug is effective, as well as the peak response that can be expected from the drug. The relevance of doseresponse curves to drug-receptor interactions is discussed further in Chapter 4. Response Potency One criterion used frequently when comparing drugs is the concept of potency. Potency is related to the dose that produces a given response in a specific amplitude. Consequently, the term potency is often taken to be much more significant than it really is. At some threshold dose, the response begins to occur and continues to increase in magnitude before reaching a plateau. The plateau indicates that there will be no further increment in the response, even if the dosage continues to be increased. The point at which there is no further increase in the response is known as the ceiling effect, or maximal effect, of the drug. What follows is a brief description of the primary ways that the relative safety of a drug can be determined. In reality, individual differences in the clinical population cause variations in drug responses that need to be considered when trying to assess whether a drug is safe as well as effective. Consequently, the relationship between the dose of the drug and the occurrence of a certain response is measured in a large group of people (or animals if the drug is being tested preclinically). The response is not graded; it is either present or it is absent in each member of the population. For example, a headache medication is administered in an increasing dosage to 1,000 people. At a certain dose, some of the individuals will respond to the drug and report the absence of their headache. As the dosage is increased, more and more individuals will experience pain relief because of the medication, until finally 100 percent of the population report that their headaches are gone. Median Toxic Dose In the aforementioned example, relief from pain was the desired response, which is often termed the beneficial effect. To continue the earlier example, higher doses of the same medication may be associated with the appearance of a specific toxic effect, such as acute gastric hemorrhage. As the dosage is increased, more and more individuals will then begin to exhibit that particular adverse effect. As addressed in this chapter, clinical pharmacology deals primarily with the beneficial effects of specific drugs on humans and the manner in which these drugs exert their therapeutic effects. This chapter also addressed the strategies used to name drugs and described the distinction between generic and trade (brand) names for a given drug. Furthermore, clinicians should know that drugs used therapeutically are subjected to extensive testing prior to approval for use in humans and that they are classified as either prescription or over-the-counter, depending on their dosage, effectiveness, and safety profile. Finally, this chapter described certain characteristic relationships between the dose of a drug and the response or effect it produces. Such relationships can provide useful information about drug efficacy and potency and about the relative safety of different compounds. Other prescription agents such as cancer chemotherapeutics (methotrexate, vincristine, etc. The consequences of not using the drug outweigh the risks of some of the toxic effects. The use of generic drugs in prevention of chronic disease is far more cost-effective than thought, and may save money. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence. The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence. Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder. Promoting, improving and accelerating the drug development and approval processes. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs Accelerated approval of oncology products: the food and drug administration experience. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials. What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis. Commercial speech and off-label drug uses: what role for wide acceptance, general recognition and research incentives The ban on "off-label" pharmaceutical promotion: constitutionally permissible prophylaxis against false or misleading commercial speech Comparative risks of non-prescription analgesics: a structured topic review and research priorities. Increasing access to nonprescription medicines: a global public health challenge and opportunity. Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Adverse drug interactions involving common prescription and over-the-counter analgesic agents. Improving the decision-making process for nonprescription drugs: a framework for benefit-risk assessment. Pharmacokinetics and pharmacodynamics: rational dosing and the time course of drug action. An introduction to pharmacokinetic principles will help you understand why specific drugs are administered in certain ways. Why, for example, can some drugs be administered orally while others need to be administered by injection, inhalation, or other non-oral routes Finally, it is critical to know how the body metabolizes and eliminates a drug so that you can be aware of problems that might arise if drug metabolism is altered by illness, disease, or other factors. Other pharmacokinetic issues, such as drug absorption, distribution, and storage, will then be addressed. For a more detailed description of the specific methodology involved in drug administration, the references at the end of this chapter include several excellent resources on this topic. Oral administration is the easiest method for taking medications, especially when self-administration is necessary or desired. The oral route is also relatively safe because drugs enter the system in a fairly controlled manner. Most medications that are administered orally are absorbed from the small intestine, thus utilizing the large surface area of the intestinal microvilli to enhance their entry into the body. Large, nonlipid-soluble compounds are absorbed very poorly from the alimentary canal and will eventually be lost through the feces. Each route has several variations, and each offers distinct advantages and disadvantages. This encapsulating technique enables the oral administration of drugs that were formerly administered only through injection or some other parenteral route.

Oxytrol 5 mg purchase. A day-in-the-life of depression.

References

• Panneton JM, Teh SH, Cherry KJ Jr, et al. Aortic fenestration for acute or chronic aortic dissection: an uncommon but effective procedure. J Vasc Surg. 2000;32:711-721.
• Ancoli-Israel S, Gehrman P, Kripke DF, et al. Longterm follow-up of sleep disordered breathing in older adults. Sleep Med 2001;2(6):511-6.
• Bath PM, Lindenstrom E, Boysen G, et al. Tinzaparin in acute ischaemic stroke (TAIST): A randomised aspirin-controlled trial. Lancet 2001;358:702-10.
• Koblin BA, Hessol NA, Zauber AG, et al. Increased incidence of cancer among homosexual men, New York City and San Francisco, 1978-1990.
• Okubo Y, Miyamoto T, Suwazano Y, et al. Alcohol consumption and blood pressure in Japanese men. Alcohol 2001;23:149.
• Lui FY, Davis KA. Gastroduodenal perforation: maximal or minimal intervention? Scand J Surg. 2010;99:73.